 | Up a level |
Journal Article
Gluz, O., Kreipe, H., Christgen, M., Salem, M., Clemens, M., Markmann, S., Liedtke, B., Barinoff, J., Aktas, B., Henschen, S., Luebbe, K., Shak, S., Baehner, R., Liedtke, C., Nitz, U. and Harbeck, N. (2010). Pilot Phase of the Randomized PlanB Trial: Prospective Comparison of Molecular Classification, Oncotype DX (R) and Clinical-Pathological Characteristics in Hormone-Receptor (HR) Positive Primary Breast Cancer. Cancer Res., 70. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445
Laakmann, E., Witzel, I., Neunhoeffer, T., Park-Simon, T-W., Weide, R., Riecke, K., Polasik, A., Schmidt, M., Puppe, J., Mundhenke, C., Luebbe, K., Hesse, T., Thill, M., Zahm, D-M., Denkert, C., Fehm, T., Nekljudova, V., Rey, J., Loibl, S. and Mueller, V. (2021). Characteristics of patients with brain metastases from HER2-positive breast cancer. Ann. Oncol., 32. S. S63 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Pohl, E., Schneeweiss, A., Hauke, J., Moebus, V., Furlanetto, J., Denkert, C., Fasching, P. A., Hanusch, C., Tesch, H., Weber-Lassalle, N., Mueller, V., Rhiem, K., Untch, M., Luebbe, K., Lederer, B., Jackisch, C., Nekljudova, V., Schmutzler, R. K., Hahnen, E. and Loibl, S. (2018). Germline mutation status and therapy response in patients with triple-negative breast cancer (TNBC): Results of the GeparOcto study. Ann. Oncol., 29. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Riecke, K., Laakmann, E., Neunhoffer, T., Park-Simon, T-W., Weide, R., Schmidt, M., Polasik, A., Puppe, J., Mundhenke, C., Luebbe, K., Hesse, T., Thill, M., Zahm, D-M., Denkert, C., Fehm, T., Nekljudova, V., Rey, J., Loibl, S., Mueller, V. and Witzel, I. (2022). Long-term survival of breast cancer patients with brain metastases: Subanalysis of the BMBC registry. Ann. Oncol., 33. S. S202 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Schneeweiss, A., Moebus, V., Tesch, H., Klare, P., Denkert, C., Kast, K., Hanusch, C., Link, T., Untch, M., Jackisch, C., Blohmer, J-U., Fasching, P. A., Solbach, C., Huober, J., Rhiem, K. E., Nekljudova, V., Luebbe, K. and Loibl, S. (2020). Survival analysis of the randomized phase III GeparOcto trial comparing neoadjuvant chemotherapy (NACT) of iddEPC versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triplenegative breast cancer, TNBC) (PM(Cb)) for patients (pts) with highrisk early breast cancer (BC). Ann. Oncol., 31. S. S303 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041